Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer

Urology

Volumn 62, Issue 5, 2003, Pages 952-957

  Vasala, Kaija ^a   Pääkkö, Paavo ^a   Turpeenniemi Hujanen, Taina ^a,b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A;

ANTIGEN DETECTION; ARTICLE; BLADDER CARCINOMA; BLADDER METASTASIS; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE FIXATION; TISSUE SECTION;

EID: 0242495736     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00660-5     Document Type: Article

References (20)

1. Ferlay J., Bray F., Sankila R., et al. Cancer Incidence, Mortality and Prevalence in the European Union. 1999;IARC Press, Lyon.
2. Shapiro S.D. Matrix metalloproteinase degradation of extracellular matrix biological consequences. Curr Opin Cell Biol. 10:1998;602-608.
3. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89:1997;1260-1270.
4. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem. 274:1999;21491-21494.
5. Talvensaari-Mattila A., Pääkkö P.M., Höyhtyä M., et al. Matrix metalloproteinase-2 immunoreactive protein a marker of aggressiveness in breast carcinoma. Cancer. 83:1998;1153-1162.
6. Väisänen A., Tuominen H., Kallioinen M., et al. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumor progression and may have prognostic value. J Pathol. 180:1996;283-289.
7. Väisänen A., Kallioinen M., von Dickhoff K., et al. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - a new prognostic marker in uveal melanoma? J Pathol. 188:1999;56-62.
8. Emmert-Buck M.R., Emonard H.P., Corcoran M.L., et al. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett. 364:1995;28-32.
9. Liabakk N.-B., Talbot I., Smith R.A., et al. Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 56:1996;190-196.
10. Papathoma A.S., Petraki C., Grigorakis A., et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res. 20:2000;2009-2013.
11. Grignon D.J., Sakr W., Toth M., et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 56:1996;1654-1659.
12. International Union Against Cancer. TNM Classification of Malignant Tumours. Geneva, Switzerland, Wiley-Liss, 1997.
13. Hsu S.M., Raine L., Fanger H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 29:1981;557-580.
14. Höyhtyä M., Fridman R., Komarek D., et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer. 56:1994;500-505.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
16. Lipponen P.K., Eskelinen M.J., Kiviranta J., et al. Prognosis of transitional cell bladder cancer a multivariate prognostic score for improved prediction. J Urol. 146:1991;1535-1540.
17. Kanayama H., Yokota K., Kurokawa Y., et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 82:1998;1359-1366.
18. Turpeenniemi-Hujanen T., Thorgeirsson U.P., Rao C.N., et al. Laminin increases the release of type IV collagenase from malignant cells. J Biol Chem. 261:1989;1883-1889.
19. Hindermann W., Berndt A., Haas K., et al. Immunohistochemical demonstration of the γ2 chain of laminin-5 in urinary bladder carcinoma impact for diagnosis and prognosis. Cancer Detect Prev. 27:2003;109-115.
20. Gerhards S., Jung K., Koening F., et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with high stage and grade of bladder carcinoma. Urology. 57:2001;675-679.